比较根据治疗范围指南建议从华法林转换为直接口服抗凝剂前后的患者结局。
Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations.
机构信息
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor.
Department of Heart and Vascular Services, Beaumont Hospital, Royal Oak, Michigan.
出版信息
JAMA Netw Open. 2022 Jul 1;5(7):e2222089. doi: 10.1001/jamanetworkopen.2022.22089.
Abstract
This cohort study evaluates stroke and major bleeding rates before and after switching from warfarin to a direct oral anticoagulant (DOAC) in patients grouped by pre-switch time-in-therapeutic range guideline thresholds.
摘要
本队列研究评估了在根据预切换时治疗范围指南阈值分组的患者中，从华法林切换为直接口服抗凝剂（DOAC）前后的卒中发生率和大出血发生率。
相似文献
1
Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations.比较根据治疗范围指南建议从华法林转换为直接口服抗凝剂前后的患者结局。
JAMA Netw Open. 2022 Jul 1;5(7):e2222089. doi: 10.1001/jamanetworkopen.2022.22089.
2
Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.静脉血栓栓塞症抗凝延长治疗患者换用直接口服抗凝剂后对患者满意度的影响：SWAN 研究。
PLoS One. 2020 Jun 4;15(6):e0234048. doi: 10.1371/journal.pone.0234048. eCollection 2020.
3
Trends in oral anticoagulant use in Qatar: a 5-year experience.卡塔尔口服抗凝剂使用趋势：五年经验
J Thromb Thrombolysis. 2017 Apr;43(3):411-416. doi: 10.1007/s11239-017-1474-4.
4
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
5
Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.采用混合治疗比较的荟萃分析方法评估口服抗凝剂用于静脉血栓栓塞症的长期治疗。
Clin Ther. 2014 Oct 1;36(10):1454-64.e3. doi: 10.1016/j.clinthera.2014.06.033. Epub 2014 Aug 3.
6
Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic.在2019冠状病毒病大流行期间将华法林患者转换为直接口服抗凝剂。
Thromb Res. 2021 Jan;197:192-194. doi: 10.1016/j.thromres.2020.11.004. Epub 2020 Nov 7.
7
Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.当代口服抗凝剂在亚洲非瓣膜性心房颤动患者中的疗效和安全性。
Stroke. 2019 Aug;50(8):2245-2249. doi: 10.1161/STROKEAHA.119.025536. Epub 2019 Jun 18.
8
Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.利伐沙班与华法林在极度肥胖和高体重人群中的卒中预防和静脉血栓栓塞症治疗中的比较。
Ann Pharmacother. 2020 Apr;54(4):344-350. doi: 10.1177/1060028019886092. Epub 2019 Oct 31.
9
Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.利伐沙班与华法林用于延长深静脉血栓栓塞症治疗的成本分析
Phlebology. 2018 Feb;33(1):53-59. doi: 10.1177/0268355516688358. Epub 2017 Jan 6.
10
Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.2010年至2015年挪威心房颤动患者使用华法林和直接口服抗凝剂的趋势
Eur J Clin Pharmacol. 2017 Nov;73(11):1417-1425. doi: 10.1007/s00228-017-2296-1. Epub 2017 Jul 22.
引用本文的文献
1
Comparison of the DOAC Dipstick Test on Urine Samples With Chromogenic Substrate Methods on Plasma Samples in Outpatients Treated With Direct Oral Anticoagulants.直接口服抗凝剂治疗的门诊患者尿液样本 DOAC 检测条与血浆样本显色底物方法的比较。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231179684. doi: 10.1177/10760296231179684.
本文引用的文献
1
Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation Patients.非瓣膜性心房颤动患者发生严重及临床相关非严重出血事件后的抗凝变化
J Pharm Pract. 2023 Jun;36(3):542-547. doi: 10.1177/08971900211064189. Epub 2021 Dec 28.
2
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动诊断和管理指南：欧洲心脏病学会（ESC）心房颤动诊断和管理特别工作组，由ESC欧洲心律协会（EHRA）特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
3
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.抗栓治疗心房颤动：CHEST 指南和专家报告。
Chest. 2018 Nov;154(5):1121-1201. doi: 10.1016/j.chest.2018.07.040. Epub 2018 Aug 22.
4
Practical management of anticoagulation in patients with atrial fibrillation.心房颤动患者抗凝治疗的实用管理。
J Am Coll Cardiol. 2015 Apr 7;65(13):1340-1360. doi: 10.1016/j.jacc.2015.01.049.
5
The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.CHADS2和CHA2DS2-VASc评分对房颤出血风险的预测能力：MAQI(2)研究经验
Thromb Res. 2014 Aug;134(2):294-9. doi: 10.1016/j.thromres.2014.05.034. Epub 2014 Jun 2.
6
A method to determine the optimal intensity of oral anticoagulant therapy.一种确定口服抗凝治疗最佳强度的方法。
Thromb Haemost. 1993 Mar 1;69(3):236-9.
Zotero 插件